Severe memory decline along with unaffected executive functions under 400 mg/day of cenobamate leading to a collapse in school performance

References

• Bootsma, H. P., Ricker, L., Hekster, Y. A., Hulsman, J., Lambrechts, D., Majoie, M., Schellekens, A., de Krom, M., & Aldenkamp, A. P. (2009). The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure: European Journal of Epilepsy, 18(5), 327–331. https://doi.org/10.1016/j.seizure.2008.11.006
   PubMed Web of Science ®Google Scholar
• Chung, S. S., French, J. A., Kowalski, J., Krauss, G. L., Lee, S. K., Maciejowski, M., Rosenfeld, W. E., Sperling, M. R., Mizne, S., & Kamin, M. (2020). Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology, 94(22), e2311–e2322. https://doi.org/10.1212/WNL.0000000000009530
   PubMed Web of Science ®Google Scholar
• Eddy, C. M., Rickards, H. E., & Cavanna, A. E. (2011). The cognitive impact of antiepileptic drugs. Therapeutic Advances in Neurological Disorders, 4(6), 385–407. https://doi.org/10.1177/1756285611417920
   PubMedGoogle Scholar
• Gilliam, F. G., Fessler, A. J., Baker, G., Vahle, V., Carter, J., & Attarian, H. (2004). Systematic screening allows reduction of adverse antiepileptic drug effects: A randomized trial. Neurology, 62(1), 23–27. https://doi.org/10.1212/WNL.62.1.23
   PubMed Web of Science ®Google Scholar
• Hautzinger, M., Bailer, M., Woral, H., & Keller, F. (1995). Beck-Depressions-Inventar (BDI). Testhandbuch (2nd ed.). Hans Huber.
   Google Scholar
• Helmstaedter, C. (2019). EpiTrack® – Veränderungssensitives kognitives Screening zur Beurteilung der Aufmerksamkeit und der Exekutivfunktionen für die Qualitäts- und Ergebniskontrolle der Behandlung von Patienten mit Epilepsie (3Auflage). Eisai GmbH. https://www.eisai.de/fachkreise/neurologie/service/#EpiTrack
   Google Scholar
• Helmstaedter, C., Elger, C. E., & Witt, J. A. (2016). The effect of quantitative and qualitative antiepileptic drug changes on cognitive recovery after epilepsy surgery. Seizure: European Journal of Epilepsy, 36, 63–69. https://doi.org/10.1016/j.seizure.2016.02.001
   PubMed Web of Science ®Google Scholar
• Helmstaedter, C., Lendt, M., & Lux, S. (2001). VLMT Verbaler Lern- und Merkfähigkeitstest. Beltz Test GmbH.
   Google Scholar
• Helmstaedter, C., Meschede, C., Mastani, S., Moskau-Hartmann, S., Rademacher, M., von Wrede, R., & Witt, J.-A. (2024). Normalization and cross-sectional validation of an extended Adverse Event Profile (E AEP) in a large cohort of patients with epilepsy. Seizure: European Journal of Epilepsy, 114, 9–17. https://doi.org/10.1016/j.seizure.2023.11.010
   PubMed Web of Science ®Google Scholar
• Helmstaedter, C., Pohl, C., Hufnagel, A., & Elger, C. E. (1991). Visual learning deficits in nonresected patients with right temporal lobe epilepsy. Cortex; a Journal Devoted to the Study of the Nervous System and Behavior, 27(4), 547–555. https://doi.org/10.1016/s0010-9452(13)80004-4
   PubMed Web of Science ®Google Scholar
• Helmstaedter, C., & Witt, J.-A. (2012). Multifactorial etiology of interictal behavior in frontal and temporal lobe epilepsy. Epilepsia, 53(10), 1765–1773. https://doi.org/10.1111/j.1528-1167.2012.03602.x
   PubMed Web of Science ®Google Scholar
• Helmstaedter, C., & Witt, J.-A. (2013). The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting. Epilepsy & Behavior, 26(2), 182–187. https://doi.org/10.1016/j.yebeh.2012.11.052
   PubMed Web of Science ®Google Scholar
• Kanner, A. M., Patten, A., Ettinger, A. B., Helmstaedter, C., Meador, K. J., & Malhotra, M. (2021). Does a psychiatric history play a role in the development of psychiatric adverse events to perampanel … and to placebo? Epilepsy & Behavior, 125, 108380. https://doi.org/10.1016/j.yebeh.2021.108380
   PubMed Web of Science ®Google Scholar
• Kanner, A. M., Wuu, J., Faught, E., Tatum, W. O., Fix, A., French, J. A., & PADS Investigators. (2003). A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy & Behavior, 4(5), 548–552. https://doi.org/10.1016/j.yebeh.2003.07.007
   PubMed Web of Science ®Google Scholar
• Krauss, G. L., Chung, S. S., Ferrari, L., Stern, S., & Rosenfeld, W. E. (2024). Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies. Epilepsy & Behavior, 151(18), 109605. https://doi.org/10.1016/j.yebeh.2023.109605
   PubMedGoogle Scholar
• Lattanzi, S., Trinka, E., Zaccara, G., Striano, P., Del Giovane, C., Silvestrini, M., & Brigo, F. (2020). Adjunctive cenobamate for focal-onset seizures in adults: A systematic review and Meta-analysis. CNS Drugs, 34(11), 1105–1120. https://doi.org/10.1007/s40263-020-00759-9
   PubMed Web of Science ®Google Scholar
• Lehrl, S. (2005). Mehrfachwahl-Wortschatz-Intelligenztest MWT-B (5th ed.). Spitta Verlag.
   Google Scholar
• Loring, D. W., Marino, S., & Meador, K. J. (2007). Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychology Review, 17(4), 413–425. https://doi.org/10.1007/s11065-007-9043-9
   PubMed Web of Science ®Google Scholar
• Makridis, K. L., & Kaindl, A. M. (2023). Real-world experience with cenobamate: A systematic review and meta-analysis. Seizure: European Journal of Epilepsy, 112, 1–10. https://doi.org/10.1016/j.seizure.2023.09.006
   PubMed Web of Science ®Google Scholar
• Meschede, C., Witt, J. A., Brömling, S., Moskau-Hartmann, S., Rademacher, M., Surges, R., von Wrede, R., & Helmstaedter, C. (2020). Changes in cognition after introduction or withdrawal of zonisamide versus topiramate in epilepsy patients: A retrospective study using Bayes statistics. Epilepsia, 61(7), 1481–1490. https://doi.org/10.1111/epi.16576
   PubMed Web of Science ®Google Scholar
• Meschede, C., Witt, J., Rademacher, M., Wrede, R. D. V., Elger, C. E., & Helmstaedter, C. (2018). Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting. Seizure: European Journal of Epilepsy, 58, 141–146. https://doi.org/10.1016/j.seizure.2018.04.015
   PubMed Web of Science ®Google Scholar
• Roberti, R., De Caro, C., Iannone, L. F., Zaccara, G., Lattanzi, S., & Russo, E. (2021). Pharmacology of cenobamate: Mechanism of action, pharmacokinetics, drug-drug interactions and tolerability. CNS Drugs, 35(6), 609–618. https://doi.org/10.1007/s40263-021-00819-8
   PubMed Web of Science ®Google Scholar
• Schuetz, E., Wagner, K., Metternich, B., Papadopoulou, G., Kravalis, K., Heers, M., Martínez-Lizana, E., Castillo-Rodriguez, M., Altenmüller, D. M., Schulze-Bonhage, A., & Hirsch, M. (2022). Effects of cenobamate on cognitive performance of epilepsy patients. Seizure: European Journal of Epilepsy, 102(July), 129–133. https://doi.org/10.1016/j.seizure.2022.10.004
   PubMedGoogle Scholar
• Seyer, F., Witt, J. A., Taube, J., & Helmstaedter, C. (2018). The efficacy of a short-term multidisciplinary epilepsy program. Epilepsy and Behavior, 86, 98–101. https://doi.org/10.1016/j.yebeh.2018.06.017
   PubMed Web of Science ®Google Scholar
• Song, W. S., Cho, Y. S., Oh, S. P., Yoon, S. H., Kim, Y. S., & Kim, M. H. (2022). Cognitive and behavioral effects of the anti-epileptic drug cenobamate (YKP3089) and underlying synaptic and cellular mechanisms. Neuropharmacology, the Neuropharmacology of Social Behavior: From Bench to Bedside, 221(September), 109292. https://doi.org/10.1016/j.neuropharm.2022.109292
   Google Scholar
• Strzelczyk, A., & Schubert-Bast, S. (2022). Psychobehavioural and cognitive adverse events of Anti-seizure medications for the treatment of developmental and epileptic encephalopathies. CNS Drugs, 36(10), 1079–1111. https://doi.org/10.1007/s40263-022-00955-9
   PubMed Web of Science ®Google Scholar
• Witt, J.-A., Elger, C. E., & Helmstaedter, C. (2013). Which drug-induced side effects would be tolerated in the prospect of seizure control? Epilepsy & Behavior, 29(1), 141–143. https://doi.org/10.1016/j.yebeh.2013.07.013
   PubMed Web of Science ®Google Scholar
• Witt, J.-A., Elger, C. E., & Helmstaedter, C. (2015). Adverse cognitive effects of antiepileptic pharmacotherapy: Each additional drug matters. European Neuropsychopharmacology, 25(11), 1954–1959. https://doi.org/10.1016/j.euroneuro.2015.07.027
   PubMed Web of Science ®Google Scholar
• Witt, J.-A., Elger, C. E., & Helmstaedter, C. (2018). Short-term and longer-term effects of brivaracetam on cognition and behavior in a naturalistic clinical setting – Preliminary data. Seizure: European Journal of Epilepsy, 62(September), 49–54. https://doi.org/10.1016/j.seizure.2018.09.016
   PubMedGoogle Scholar
• Witt, J.-A., & Helmstaedter, C. (2013). Monitoring the cognitive effects of antiepileptic pharmacotherapy–approaching the individual patient. Epilepsy & Behavior, 26(3), 450–456. https://doi.org/10.1016/j.yebeh.2012.09.015
   PubMed Web of Science ®Google Scholar
• Witt, J.-A., & Helmstaedter, C. (2017). How can we overcome neuropsychological adverse effects of antiepileptic drugs? Expert Opinion on Pharmacotherapy, 18(6), 1–4. https://doi.org/10.1080/14656566.2017.1309025
   PubMed Web of Science ®Google Scholar
• Witt, J.-A., Hollmann, K., & Helmstaedter, C. (2008). The impact of lesions and epilepsy on personality and mood in patients with symptomatic epilepsy: A pre- to postoperative follow-up study. Epilepsy Research, 82(2–3), 139–146. https://doi.org/10.1016/j.eplepsyres.2008.07.011
   PubMed Web of Science ®Google Scholar
• Witt, J.-A., Meschede, C., & Helmstaedter, C. (2021). Hazardous employment of invalid measures for cognitive outcome assessment: You only see what your test can show you. Epilepsy & Behavior, 117, 107865. https://doi.org/10.1016/j.yebeh.2021.107865
   PubMed Web of Science ®Google Scholar
• Witt, J.-A., Rademacher, M., von Wrede, R., Surges, R., & Helmstaedter, C. (2022). Cognitive reawakening and improved quality of life achieved after discontinuing 16 years of anti-seizure treatment with topiramate. Neurocase, 28(1), 102–106. https://doi.org/10.1080/13554794.2022.2032187
   PubMed Web of Science ®Google Scholar